NCT06337162

Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)

Name: Clinical Trial NCT06337162
Creator: Abramson Cancer Center at Penn Medicine
Keywords: Hepatocellular Carcinoma, INCB099280, Phase 1, drug, clinical trial, United States of America

A Pilot Study of Neoadjuvant INCB099280 in Patients With Hepatocellular Carcinoma Awaiting Liver Transplant

Abramson Cancer Center at Penn Medicine·Phase 1·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Hepatocellular Carcinoma
Drug/Device/Intervention: INCB099280
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Abramson Cancer Center at Penn Medicine
Location: Philadelphia, United States of America

Timeline & enrollment

Phase: Phase 1
Start date: May 01, 2024
End date: Sep 01, 2028
Enrollment: 15 participants

Primary outcome

Acute Cellular Rejection of Liver Transplant Attributed to Study Therapy

Summary

This is a pilot safety study of the oral PD-L1 inhibitor INCB099280 in patients with HCC awaiting liver transplant.

ICD-10 classifications

Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06337162
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06337162 through Pure Global AI's free database. This Phase 1 trial is sponsored by Abramson Cancer Center at Penn Medicine and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 15 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.